BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Capdevila J, Ramos FJ, Macarulla T, Elez E, Tabernero J. The role of salvage treatment in advanced colorectal cancer. Crit Rev Oncol Hematol 2009;71:53-61. [PMID: 18977669 DOI: 10.1016/j.critrevonc.2008.09.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Houts AC, Ogale S, Zafar Y, Hubbard JM, Satram-Hoang S, Sommer N, Walker MS. Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings. J Gastrointest Cancer 2019;50:16-22. [PMID: 29058260 DOI: 10.1007/s12029-017-0017-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
2 Walker MS, Pharm EY, Kerr J, Yim YM, Stepanski EJ, Schwartzberg LS. Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer. BMC Res Notes 2012;5:314. [PMID: 22716038 DOI: 10.1186/1756-0500-5-314] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
3 Liu S, Jiang C, Yang L, Huang J, Peng R, Wang X, He W, Bai L, Zhou Y, Zhang B, Xia L. First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study. Sci Rep 2020;10:12336. [PMID: 32704062 DOI: 10.1038/s41598-020-69230-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kim SH, Shin SJ, Kim SY, Lee SH, Park YS, Park SH, Lee KH, Kim TW, Hong YS, Ahn JB. Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial. Cancer Chemother Pharmacol 2012;69:91-7. [PMID: 21607556 DOI: 10.1007/s00280-011-1668-y] [Reference Citation Analysis]
5 Fornaro L, Vasile E, Masi G, Loupakis F, Baldi GG, Allegrini G, Salvatore L, Cremolini C, Cupini S, Cortesi E, Tuzi A, Granetto C, Brunetti IM, Ricci S, Falcone A. Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen. Clin Colorectal Cancer 2012;11:71-6. [PMID: 21903485 DOI: 10.1016/j.clcc.2011.06.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
6 Geevarghese SK, Geller DA, de Haan HA, Hörer M, Knoll AE, Mescheder A, Nemunaitis J, Reid TR, Sze DY, Tanabe KK. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther. 2010;21:1119-1128. [PMID: 20486770 DOI: 10.1089/hum.2010.020] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 6.5] [Reference Citation Analysis]
7 Houts AC, Ogale S, Sommer N, Satram-Hoang S, Walker MS. Treatment Patterns and Outcomes in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Treated in First Line with Bevacizumab- or Cetuximab-Containing Regimens. J Gastrointest Cancer 2019;50:69-77. [PMID: 29168112 DOI: 10.1007/s12029-017-0027-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
8 Doroshow JH. Selecting Systemic Cancer Therapy One Patient at a Time: Is There a Role for Molecular Profiling of Individual Patients With Advanced Solid Tumors? JCO 2010;28:4869-71. [DOI: 10.1200/jco.2010.31.1472] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
9 Ottone A, Bellini E, Ferrero A, Baratelli C, Taberna E, Bitossi R, Brizzi MP, Tampellini M. A case of long-term survival after repeated response to oxaliplatin-based chemotherapy and repeated thermoablation of liver metastases from colorectal cancer. Should we introduce the concept of oxaliplatin-resistant tumors? Tumori 2013;99:e91-5. [DOI: 10.1177/030089161309900323] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
10 Kang EJ, Choi YJ, Kim JS, Kim ST, Park KH, Choi IK, Oh SC, Seo JH, Shin SW, Kim JS, Kim YH. Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma: Chemotherapy in refractory colon cancer. Asia-Pacific Journal of Clinical Oncology 2010;6:286-91. [DOI: 10.1111/j.1743-7563.2010.01334.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]